Research
Hormonal
Bariatric surgery does NOT significantly reduce the incidence of esophageal, gastric, thyroid, kidney, prostate cancers, or multiple myeloma compared to conventional treatment.
While bariatric surgery reduces many obesity-related cancers, it does not appear to significantly lower the risk of esophageal, gastric, thyroid, kidney, prostate cancers, or multiple myeloma.
GoodRefutesMEDIUM confidence
There was no significant reduction in the incidence of oesophageal, gastric, thyroid, kidney, prostate cancer or multiple myeloma after bariatric surgery as compared to patients with morbid obesity who did not have bariatric surgery.
Why this rating
Based on meta-analysis, though some of these cancers had fewer studies.
Source
Systematic Review and Meta-Analysis of the Impact of Bariatric Surgery on Future Cancer Risk
Robert B. Wilson et al. · International Journal of Molecular Sciences · 2023
DOI 10.3390/ijms24076192
Meta-analysis · 32 studiesCited 121×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Bariatric surgery significantly reduces the overall incidence of cancer, obesity-related cancers, and cancer-associated mortality in patients with morbid obesity compared to conventional treatment.Good
- Bariatric surgery significantly reduces the incidence of specific obesity-related cancers, including hepatocellular, colorectal, pancreatic, gallbladder, breast, endometrial, and ovarian cancers.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →